IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.
“With this exclusive license, IntelGenx has the opportunity to be the first and only Tadalafil film product on the U.S. ED market while the ‘166 dosing patent remains in force,” Dr. Horst Zerbe, president and CEO of IntelGenx, said in a statement.
“Exclusive access to Lilly’s dosing patent will further accelerate our partnering activities while potentially securing our early entry into the lucrative U.S. ED market,” he added.
Subject to FDA approval, the exclusive license allows IntelGenx to commercialize its Tadalafil ED VersaFilm product in the U.S. prior to the expiration of the ‘166 dosing patent. IntelGenx is seeking a strategic partnership for the commercialization of Tadalafil VersaFilm.
In addition, IntelGenx has developed a proprietary process and formulation for manufacturing the Tadalafil ED VersaFilm product and plans to supply the product to multiple markets around the world.
